AU2004272280C1 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors Download PDF

Info

Publication number
AU2004272280C1
AU2004272280C1 AU2004272280A AU2004272280A AU2004272280C1 AU 2004272280 C1 AU2004272280 C1 AU 2004272280C1 AU 2004272280 A AU2004272280 A AU 2004272280A AU 2004272280 A AU2004272280 A AU 2004272280A AU 2004272280 C1 AU2004272280 C1 AU 2004272280C1
Authority
AU
Australia
Prior art keywords
alkyl
ethyl
hydroxy
alkylaryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004272280A
Other languages
English (en)
Other versions
AU2004272280A1 (en
AU2004272280B2 (en
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2004272280A1 publication Critical patent/AU2004272280A1/en
Publication of AU2004272280B2 publication Critical patent/AU2004272280B2/en
Priority to AU2011202994A priority Critical patent/AU2011202994B2/en
Application granted granted Critical
Publication of AU2004272280C1 publication Critical patent/AU2004272280C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2004272280A 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors Ceased AU2004272280C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202994A AU2011202994B2 (en) 2003-09-13 2011-06-21 Matrix metalloproteinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
GB0321538.1 2003-09-13
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202994A Division AU2011202994B2 (en) 2003-09-13 2011-06-21 Matrix metalloproteinase inhibitors

Publications (3)

Publication Number Publication Date
AU2004272280A1 AU2004272280A1 (en) 2005-03-24
AU2004272280B2 AU2004272280B2 (en) 2011-04-21
AU2004272280C1 true AU2004272280C1 (en) 2011-10-27

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004272280A Ceased AU2004272280C1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Country Status (28)

Country Link
US (3) US7601729B2 (enExample)
EP (3) EP2295408A1 (enExample)
JP (3) JP2007505081A (enExample)
KR (3) KR20060120648A (enExample)
CN (1) CN1849306B (enExample)
AT (2) ATE502922T1 (enExample)
AU (1) AU2004272280C1 (enExample)
BR (1) BRPI0413791A (enExample)
CA (1) CA2538315C (enExample)
CY (1) CY1109400T1 (enExample)
DE (2) DE602004031991D1 (enExample)
DK (1) DK1663970T3 (enExample)
ES (2) ES2314436T3 (enExample)
GB (1) GB0321538D0 (enExample)
HR (1) HRP20080668T3 (enExample)
IL (1) IL173305A (enExample)
IS (2) IS2622B (enExample)
MA (1) MA28039A1 (enExample)
MX (1) MXPA06002458A (enExample)
NO (1) NO20060540L (enExample)
NZ (2) NZ545211A (enExample)
PL (1) PL1663970T3 (enExample)
PT (1) PT1663970E (enExample)
RU (2) RU2370488C2 (enExample)
SG (1) SG145685A1 (enExample)
SI (1) SI1663970T1 (enExample)
WO (1) WO2005026120A1 (enExample)
ZA (1) ZA200602070B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) * 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP2926808A1 (en) 2012-11-28 2015-10-07 Administración General De La Communidad Autónoma De Euskadi Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2199195A (en) * 1994-04-28 1995-11-29 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
CZ172498A3 (cs) * 1995-12-06 1998-12-16 Astra Pharmaceuticals Ltd. Sloučenina
DK0898566T3 (da) 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
MY132470A (en) * 1996-05-15 2007-10-31 Bayer Corp Substituted oxobutyric acids as matrix metalloprotease inhibitors
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
JP2005504727A (ja) * 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
US7102008B2 (en) 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
BR0314898A (pt) * 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) * 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme

Also Published As

Publication number Publication date
HK1092141A1 (en) 2007-02-02
RU2006106850A (ru) 2007-10-20
CN1849306B (zh) 2014-01-29
US8263602B2 (en) 2012-09-11
JP2011231118A (ja) 2011-11-17
EP1663970B1 (en) 2008-11-05
NO20060540L (no) 2006-04-04
RU2370488C2 (ru) 2009-10-20
EP2042488A1 (en) 2009-04-01
EP1663970A1 (en) 2006-06-07
NZ573479A (en) 2010-09-30
CA2538315A1 (en) 2005-03-24
US8343986B2 (en) 2013-01-01
IS8268A (is) 2006-01-26
US7601729B2 (en) 2009-10-13
ES2362954T3 (es) 2011-07-15
JP2012107031A (ja) 2012-06-07
WO2005026120A1 (en) 2005-03-24
IL173305A (en) 2011-01-31
RU2008146479A (ru) 2010-06-20
ATE502922T1 (de) 2011-04-15
CN1849306A (zh) 2006-10-18
SI1663970T1 (sl) 2009-04-30
BRPI0413791A (pt) 2006-11-07
AU2004272280A1 (en) 2005-03-24
DE602004031991D1 (de) 2011-05-05
ZA200602070B (en) 2007-05-30
HRP20080668T3 (hr) 2009-02-28
US20060293353A1 (en) 2006-12-28
SG145685A1 (en) 2008-09-29
PL1663970T3 (pl) 2009-04-30
MA28039A1 (fr) 2006-07-03
US20090082377A1 (en) 2009-03-26
DE602004017622D1 (de) 2008-12-18
US20100029699A1 (en) 2010-02-04
EP2295408A1 (en) 2011-03-16
CA2538315C (en) 2014-04-08
PT1663970E (pt) 2009-01-09
DK1663970T3 (da) 2009-01-12
AU2004272280B2 (en) 2011-04-21
NZ545211A (en) 2009-01-31
IS2622B (is) 2010-05-15
CY1109400T1 (el) 2014-07-02
KR20130079628A (ko) 2013-07-10
JP2007505081A (ja) 2007-03-08
ATE413384T1 (de) 2008-11-15
IS8843A (is) 2009-08-19
GB0321538D0 (en) 2003-10-15
MXPA06002458A (es) 2006-06-20
KR20120007566A (ko) 2012-01-20
EP2042488B1 (en) 2011-03-23
IL173305A0 (en) 2006-06-11
KR20060120648A (ko) 2006-11-27
ES2314436T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
US8343986B2 (en) Matrix metalloproteinase inhibitors
US7250439B2 (en) Matrix metalloproteinase inhibitors
US20080227858A1 (en) Inhibitors of matrix metalloproteinase
AU2011202994B2 (en) Matrix metalloproteinase inhibitors
US7476759B2 (en) Matrix metalloproteinase inhibitors
HK1092141B (en) Matrix metalloproteinase inhibitors
HK1148741A (en) Matrix metalloproteinase inhibitors
HK1125637A (en) Matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 JUN 2011.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 JUN 2011

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired